

REMARKS

Claims 18, 23, 24, 30 and 32 are currently amended. Claims 21-22 are cancelled. Claims 41-51 are new. No new matter is added. Reconsideration is urged in light of the amendments above and remarks below.

I. The rejection of Claims 18-24, 26, 29-31 under 35 U.S.C. 112 1st.

The Examiner has made a new matter rejection. In light of the amendments above, the issue is moot.

II. The rejection of Claims 18-24, 26, 29-35 under 35 U.S.C. 103(a)

All independent claims are currently amended. Accordingly Applicants have been entirely responsive to the Examiner's rejection. Reconsideration is urged in light of the amendments above.

III. New Claims

New claims 41-51 are added. No new matter is added. Should any additional fees be due the the USPTO is authorized to charge the deposit account of Novozymes North America, Inc., i.e., deposit account No. 50-1701.

VI. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Should any additional fees be due, the USPTO is authorized to charge the deposit account of Novozymes North America, Inc., i.e., deposit account No. 50-1701.

Respectfully submitted,

Date: October 20, 2010

/Michael W. Krenicky Reg#45411/

Michael W. Krenicky, Reg. No. 45,411
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212)840-0097